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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
transcranial magnetic stimulation (TMS) is an effective therapy in reducing depressive
symptoms in adults with bipolar depression.
STUDY DESIGN: Systematic review of three randomized controlled trials (RCTs) that were
published in the English language between 2016 and 2019.
DATA SOURCES: Data sources included articles found using PubMed as the search engine and
were selected based on their relevance to the research question as well as patient measured
outcomes.
OUTCOMES MEASURED: Outcomes measured include changes in depression symptoms
measured using the 17-item Hamilton Depression Rating Scale (HDRS-17) and Modified 24item Hamilton Depression Rating Scale (HDRS).
RESULTS: Tavares et al. found that 48% of patients with bipolar depression receiving active
TMS were treatment responders with a numbers needed to treat (NNT) of 5. Yang et al. showed
no differences in HDRS scores between groups at baseline and follow-up as shown by p=0.451
and F-score of 0.577. Finally, Fitzgerald et al. demonstrated a mean change from baseline of 3.4
in the active group and mean change from baseline of 3.0 in the sham group. While both are
significant changes, there is no significant change between treatment groups at the conclusion of
the 4 week study.
CONCLUSIONS: Even though the study by Tavares et al.1 showed a significant improvement
with TMS in depressive symptoms in adults with bipolar depression, the other two studies by
Yang et al.2 and Fitzgerald et al.4 demonstrated no difference between treatment groups. Based
on these conflicting findings, the results from this systematic review are inconclusive. Thus,
further research is needed that includes sufficiently larger sample sizes and longer treatment
trials.
KEY WORDS: Bipolar Disorder, Transcranial Magnetic Stimulation
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INTRODUCTION
Bipolar disorder is a highly disabling affective disorder characterized by mood swings
and cognitive disturbances with limited therapeutic options.1,2 The average age of onset is
between 19 and 30 but ranges from 5 to 50 years old, and the prevalence of the disease is equal
in both males and females.3 Symptoms vary between individuals and type of bipolar disorder, but
may include persistently elevated mood, irritability, extreme sadness, anxiety, impaired
judgment, risky behavior, increased libido, racing thoughts, decreased need for sleep, weight
loss/gain, and fatigue.3 Even though the disorder is characterized by hypomania and mania
episodes, depressive episodes exceed them in duration and frequency.1 Bipolar depression, the
depressive aspect of bipolar disorder, is associated with a twenty fold increased risk of suicide,
and the duration of depressive episodes lasts three to five times as long as a manic or hypomanic
episode.4 Thus, reducing depressive symptoms in adults with bipolar depression is vital in
providing these individuals with a better quality of life.
Bipolar disorder is a prevalent condition with a worldwide prevalence of around 2-3%,
including both bipolar I and II subtypes.1 During 2010 to 2011 in the United States,
approximately 46,800 emergency room visits were made each year by persons older than 15 with
a diagnosis of bipolar disorder, with an overall rate of 3.8 visits per 1,000 persons per year. 5 This
statistic is likely even higher as the onset of bipolar disorder can begin prior to age 15. Since this
disorder affects a significant amount of the population, it comes with a substantial economic
cost. The total economic burden of bipolar disorder in the United States was $45 billion over a
decade ago. Of that total, $7 billion was a result of direct costs of inpatient and outpatient care
and nontreatment related expenditures, such as costs of criminal justice.6 Individuals with bipolar
disorder utilize health care services more frequently, and they have visits that are associated with
much higher medical costs than those without the disorder.
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The pathophysiology of bipolar disorder is unknown. However, it is known that both
genetic and environmental factors play a role as it is highly inheritable and often triggered by
traumatic life events. Because the exact pathophysiology is unknown, the treatment of bipolar
depression is more complex and difficult than that of unipolar depression. There are limited firstline therapies for treating bipolar depression, but conventional medical therapies typically
include selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), atypical
antipsychotics, anticonvulsants, and mood-stabilizing agents such as lithium. Psychotherapy,
such as cognitive-behavioral therapy (CBT) and other approaches with a clinical psychologist or
licensed professional counselor, have shown success in alleviating psychological symptoms.
Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation therapy that has
been proven to be effective in reducing depressive symptoms in those with unipolar depression. 1
It is hypothesized that TMS stimulates neurons in the region of the brain involved in mood
control and depression. Since TMS has been shown to be effective in unipolar depression and
there are limited effective first-line therapies for bipolar depression, TMS is being explored as an
alternative treatment for bipolar depression because the therapy targets mood control neurons.
The exploration of TMS as a treatment option is critical to physician assistants and other
medical providers who assess and treat bipolar disorder. It is imperative that they are aware of all
treatment options, especially those outside of the standard treatment options and those that are
noninvasive and well-tolerated, such as TMS. Bipolar disorder looks different for every
individual; therefore, a provider’s knowledge of available treatment options allows them to
weigh all risks and benefits and develop the best treatment plan for each individual patient.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not transcranial
magnetic stimulation is an effective therapy in reducing depressive symptoms in adults with
bipolar depression.
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METHODS
The studies selected for this EBM review were found using the search engine, PubMed,
while using specific inclusion and exclusion criteria. All three RCTs were found in peerreviewed journals and were published in the English language after 2009. Articles were selected
based on their clinical relevance to the research question and whether or not they included
patient oriented evidence that matters (POEM). The studies included three randomized controlled
trials (RCTs) that reviewed adults over 18 years old diagnosed with bipolar disorder who were
undergoing alternative treatment for their depressive symptoms. The intervention being observed
in each of the three studies was TMS: Tavares et al.1 used fifty five 18 hertz (Hz) trains delivered
at 120% of the motor threshold (MT) intensity at 20 second intervals, Yang et al.2 used fifty five
10 Hz trains delivered at 110% of the MT intensity at 30 second intervals, and Fitzgerald et al. 4
used twenty 10 Hz trains delivered at 110% of the MT intensity at 25 second intervals. All
studies were compared to a sham transcranial magnetic stimulation that used sham coils that
mimicked scalp sensations and the acoustic artifact of the active stimulation but without the
neuronal activation. Outcomes measured in these studies included efficacy in reducing
depressive symptoms in patients with bipolar depression measured using the 17-item Hamilton
Depression Rating Scale (HDRS-17) and Modified 24-item Hamilton Depression Rating Scale
(HDRS). All studies had patients rate their depression symptoms using these scales.
As stated above, specific inclusion and exclusion criteria were applied to all three
articles. Inclusion criteria were randomized controlled trials that were published in English
within the last 10 years and included adults 18 years and older. Exclusion criteria included no
systematic reviews, articles published prior to 2009, or subjects less than 18 years old. Table 1
demonstrates all specific inclusion and exclusion criteria for each study analyzed in this review.
Statistics reported for reduction in depressive symptoms included the following: Control Event
Rate (CER), Experimental Event Rate (EER), Relative Benefit Increase (RBI), Absolute Benefit
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Increase (ABI), Numbers Needed to Treat (NNT), F-score (F), p-value, and mean change from
baseline.
Table 1. Demographics & Characteristics of Included Studies
Study

Type

# Pts

Tavares et RCT
al., 20171

50

Age
(yrs)
18-65

Inclusion
Criteria
Adults 18-65
years old
diagnosed with
bipolar
disorders types
I or II in an
acute
depressive
episode

Yang et
al., 20192

RCT

52

18-55

Adults 18-55
years old
diagnosed with
bipolar I or II
disorder
according to
DSM-IV
criteria on
stable
antipsychotic
and mood
stabilizing
treatment

Fitzgerald
et al.,
20164

RCT

46

18-70

Adults 18-70
years old
diagnosed with
bipolar
affective
disorder in a
current episode
of treatment
resistant
depression by
DSM-IV
criteria

Exclusion Criteria

W/D

Interventions

Presence of other
neuropsychiatric
conditions per
DSM-IV criteria,
such as unipolar
depression,
schizophrenia,
substance
dependence,
dementia, TBIs,
epilepsy, or
personality
disorders;
pregnancy
Patients who met
criteria for
diagnosis of
substance/alcohol
abuse, hx of
neurologic illness
(seizures, head
trauma), EEG
abnormalities,
ECT or TMS
within the last
year, or
significant
unstable medical
illness
Patients were
excluded if they
had unstable
medical
conditions,
neurologic
disorders, history
of seizure
disorder, or were
pregnant or
lactating

7

Active deep
transcranial
magnetic
stimulation vs
sham
transcranial
magnetic
stimulation
once daily for
4 weeks,
excluding
weekends

No
comment
about
losses

Active
repetitive
transcranial
magnetic
stimulation vs
sham
repetitive
transcranial
magnetic
stimulation
for 10
consecutive
days

6

Active
repetitive
transcranial
magnetic
stimulation vs
sham
repetitive
transcranial
magnetic
stimulation
once daily for
4 weeks,
excluding
weekends
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OUTCOMES MEASURED
Outcomes measured in all three studies included changes in depression symptoms
measured using the 17-item Hamilton Depression Rating Scale (HDRS-17) and Modified 24item Hamilton Depression Rating Scale (HDRS), which are two different versions of the same
scale. All studies had patients answer the questions provided in these scales, and their answers
were used to assess the severity of their depression and their progression throughout treatment.
Scoring is based on a 17-item scale and scores of 0-7 are considered normal, 8-16 suggest mild
depression, 17-23 suggest moderate depression, and scores over 24 indicate severe depression.
RESULTS
Tavares et al.1 conducted a double-blind RCT to study the efficacy and safety of TMS in
the treatment of bipolar depression patients. Their study involved 50 participants from the
Clinics Hospital of the University of Sao Paulo ages 18 to 65 years old diagnosed with bipolar
disorder types I or II according to the DSM-IV criteria, who were in an acute depressive episode
with an HDRS-17 score of 17 or greater. The subjects needed to be free of any antidepressant
drugs; however, they were allowed to be on low dose benzodiazepine, lithium, anticonvulsants or
antipsychotic therapy. The subjects were stimulated on the left dorsolateral prefrontal cortex
(DLPFC) every day for 4 weeks, except weekends, and they were clinically assessed every week
using the HDRS-17 scale for a total of 8 weeks to include both the active phase and follow-up
phase.1 Therefore, their response to the treatment was determined using the HDRS-17 scale,
looking for a 50% improvement from their baseline. In the experimental group receiving active
TMS, the experimental event rate was 48% after 4 weeks of treatment, meaning they were
considered responders to therapy.1 Meanwhile, 24% were considered responders in the control
group receiving sham TMS.1 Their response to treatment proved TMS to be an effective therapy
in reducing depressive symptoms when compared to the control group; however, these results
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were not sustained after the group was re-assessed at week 8, which was 4 weeks after the
discontinuation of TMS. The NNT in this study was 5; therefore, for every 5 patients, 1 more
will benefit from treatment. These results are organized in Table 2.
Table 2. Treatment Responders Using HDRS-17 Scores
CER
EER
RBI
ABI
24%
48%
100%
24%

NNT
5

CER: Control Event Rate; EER: Experimental Event Rate; RBI: Relative Benefit Increase; ABI: Absolute Benefit Increase; NNT: Numbers Needed to Treat

Out of the 50 participants who entered the study, 43 finished the trial. There were two
drop outs in the sham group due to missing consecutive visits, and there were five drop outs in
the active group: two were dropped due to missing consecutive visits, two were dropped due to
the severity of their depressive symptoms, and one was dropped due to the severity of the side
effects, such as the burning scalp pain.1 Thus, adverse events were considered in this study;
however, scalp pain was the only event that was determined to be more prevalent in the active
group compared to the sham group. Additional adverse events were considered, such as
headache, neck pain, hearing difficulties, and concentration difficulties; however, those who
experienced side effects were still included in the study.1
Yang et al.2 conducted a single-blind RCT that included 52 participants ages 18 to 55
years old diagnosed with bipolar disorder types I or II according to the DSM-IV criteria, who
were outpatients at the First Hospital of Hebei Medical University and on stable antipsychotic or
mood stabilizing therapy. The purpose of this study was to determine if TMS was effective and
safe in improving depressive symptoms and cognitive function in bipolar disorder. The subjects
were stimulated on the left DLPFC every day for 10 days, and they underwent baseline and
follow up assessments using the modified 24-item HDRS scale. The data for emotional
symptoms were analyzed using a 2 x 2 repeated-measures ANOVA, with treatment group (active
TMS vs sham TMS) as the one factor and time of testing (baseline vs follow-up) as the other
factor.2 After 10 days of consecutive treatment, there were found to be no differences in HDRS
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scores between baseline and follow up as demonstrated by an F-score of 0.577 and a p-value of
0.451.2 Thus, this study failed to prove TMS as an effective therapy for those with bipolar
depression. These results are displayed in Table 3.
Table 3. Analysis of HDRS Scores
Active TMS
Sham TMS
Baseline
Follow-up
Baseline
4.80  2.784
3.20  2.141
4.96  2.919

Follow-up
3.81  2.367

F-score
0.577

p-value
0.451

There was no mention of any lost subjects in this study; therefore, without any
confirmation about losses, it must be assumed that there were losses. Additionally, there were no
serious adverse events that were reported during or after treatment with TMS, and there were no
reported drop outs due to side effects. Three participants experienced dizziness during the first
initial TMS treatment; one receiving active TMS and two receiving sham TMS.2 Thus, dizziness
was not a noteworthy adverse event related to the active treatment.
Fitzgerald et al.4 conducted a double-blind RCT to explore the therapeutic benefit of
TMS in the treatment of bipolar depression. The study included 46 participants ages 18 to 70
years old diagnosed with bipolar affective disorder in a current episode of treatment resistant
depression as defined by the DSM-IV criteria, who also have a HDRS-17 score of 20 or greater.4
The patients needed to be on stable antidepressant or psychoactive drugs without recent increases
or initiation in the last 4 weeks, and they were all recruited by referral from both community and
hospital based psychiatrists between January 2009 and May 2015.4 They were stimulated on
bilateral DLPFC, instead of a unilateral approach, every day between Monday and Friday over 4
weeks, and they were assessed using the HDRS-17 scale after two and four weeks of treatment.
The results of the HDRS-17 scores were analyzed using a mean change from baseline
calculation. At the beginning of the study, the mean baseline HDRS-17 score was 23.2 in the
active group and 23.0 in the control group.4 At the end of the 4 week study, the mean scores did
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improve to 19.8 in the active group and 20.0 in the control group, creating a mean change from
baseline of 3.4 and 3.0 respectively.4 While there were significant reductions in the HDRS-17
scores, there was no difference between the treatment groups. See Table 3.
Table 4. Efficacy of TMS as Measured by Mean Change from Baseline
Active TMS
Sham TMS
Baseline
23.2
23.0
End of Treatment (Week 4)
19.8
20.0
Mean Change from Baseline
3.4
3.0
There were six identifiable losses in this study. Of the 46 participants, four withdrew
from the active group and two withdrew from the sham group. Of the four from the active group
who withdrew, two were due to practical difficulties with attendance, one was due to withdrawn
consent, and one was due to desire to access alternative treatment. Of the two from the sham
group who withdrew, one was due to practical difficulties with attendance and the other was due
to desire to access alternative treatment.4 There were no comments about adverse events and data
on safety was not reported in this study.
DISCUSSION
Despite all three RCTs having investigated TMS as an effective therapy in reducing
depressive symptoms in bipolar depression, only one of the articles produced significant data to
suggest it to be an effective therapy. Tavares et al.1 was likely more successful since it followed
the methods utilized by a notable study that used TMS for treatment of unipolar depression
published by Levkovitz in 2015, including stimulation of the left DLPFC and an adequate trial of
TMS of four weeks. While Tavares et al.1 still showed significant improvement in depressive
symptoms with four weeks of stimulation, it did not show a sustained response and remission at
week 8. Thus, the study may have seen more substantial results if the duration of treatment was
similar to Levkovitz’s study of unipolar depression, where the brain was stimulated for 12
weeks.
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Just as Tavares et al.1 was limited by sample size and duration of treatment, the two
studies that failed to produce significant data, Yang et al.2 and Fitzgerald et al.4, were also
limited by those same two factors. None of the studies included more than 52 participants and
none exceeded active treatment greater than four weeks. While Yang et al. 2 included the largest
sample size (n=52) of the three studies, the study was limited by the duration of treatment, which
was only 10 days of consecutive treatment. Even though treatment sessions vary in length, a
typical course is four to six weeks.7 Thus, this study falls significantly short of an adequate trial
of TMS.
Fitzgerald et al.4 also conducted their study over the course of four weeks; however, it
included the smallest sample size (n=46) of the three studies, causing a lack of sufficient power
to demonstrate advantage over the sham stimulation. 4 Once this study was complete, Fitzgerald
et al.4 had calculated a sample size that would have demonstrated a significant effect on the mean
change in HDRS-17 scores, and it would require 157 participants in both the active and sham
groups.4 This suggests that an adequate sample size was not used for the study, and also suggests
that it was not used in any of the three studies. Additionally, Fitzgerald et al.4 stimulated both the
left and right DLPFC. The study may have shown more significant results if it focused on
stimulating just one side, specifically the left side which shows improvement with TMS in
unilateral depression.
All three of the studies were conducted while the patients were on concurrent drug
therapy, whether that was mood stabilizing drugs, anticonvulsants, or antidepressant drugs.
These drugs could be confounding variables; thus, significantly impacting the results of these
studies as TMS was not being assessed as monotherapy. The brain was already being altered by
the effect of these drugs; therefore, the true effects of TMS could not be assessed.
Besides the limitations of the primary research, there were limitations specific to this
systematic review. There are few existing articles from peer-reviewed journals that focus on
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TMS as an intervention in reducing depressive symptoms in bipolar disorder; therefore, the pool
of studies to analyze for this review was limited. The limitation in number made researching the
intervention in question difficult, so three of the few articles that could be found were analyzed.
Due to the small number of studies, the quality of the ones selected could be questioned.
Additional studies need to be performed to further analyze the intervention for this specific
patient population and provide a larger pool of quality studies.
Even though there is conflicting data to support TMS in this systematic review, additional
research needs to be conducted since this noninvasive procedure is efficacious in previous
unilateral depression studies. Additionally, TMS is widely available in many clinics and
hospitals across the country.7 The availability makes it a readily accessible treatment option once
the proper research is conducted to support it as a regular treatment option. TMS is covered by
most major commercial companies, such as United Healthcare, Cigna, Aetna, and BCBS.8
However, in order to qualify for insurance coverage, a patient must be diagnosed with major
depressive disorder, must have tried at least two to four different antidepressants without
improvement, and/or must have tried psychotherapy without improvement.8 Since it is generally
well-tolerated, safe, and typically covered by insurance, providers, such as doctors, physician
assistants, nurse practitioners, and more, should stay informed about the results of further studies
using TMS as a therapy in reducing depressive symptoms in adults with bipolar depression.
CONCLUSION
Even though one RCT found TMS to be an effective therapy in reducing depressive
symptoms in adults with bipolar depression, two RCTs did not produce any significant data to
suggest it to be an effective therapy. Thus, this systematic review produces conflicting evidence
to determine if TMS is an effective therapy in reducing depressive symptoms in adults with
bipolar depression. According to this review, it cannot be determined if TMS is an effective
therapy. This could be due to the methods used in each of the three studies, including sample
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size, length of treatment, location of stimulation, and concurrent drug therapy use. All three of
the RCTs are limited by sample size and treatment duration as they all consisted of less than 55
participants and none lasted longer than four weeks. Thus, TMS cannot be ruled out as an
effective treatment option for bipolar depression. Further research is warranted that includes
sufficiently larger sample sizes and longer treatment trials.
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